Your browser doesn't support javascript.
loading
Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen, Yuanli; Duan, Yajun; Yang, Xiaoxiao; Sun, Lei; Liu, Mengyang; Wang, Qixue; Ma, Xingzhe; Zhang, Wenwen; Li, Xiaoju; Hu, Wenquan; Miao, Robert Q; Xiang, Rong; Hajjar, David P; Han, Jihong.
Afiliação
  • Chen Y; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Duan Y; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Yang X; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Sun L; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Liu M; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Wang Q; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Ma X; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Zhang W; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Li X; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Hu W; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Miao RQ; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Xiang R; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Hajjar DP; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
  • Han J; From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical C
Arterioscler Thromb Vasc Biol ; 35(4): 948-59, 2015 Apr.
Article em En | MEDLINE | ID: mdl-25810299
OBJECTIVE: Activation of liver X receptor (LXR) inhibits atherosclerosis but induces hypertriglyceridemia. In vitro, it has been shown that mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor synergizes LXR ligand-induced macrophage ABCA1 expression and cholesterol efflux. In this study, we determined whether MEK1/2 (U0126) and LXR ligand (T0901317) can have a synergistic effect on the reduction of atherosclerosis while eliminating LXR ligand-induced fatty livers and hypertriglyceridemia. We also set out to identify the cellular mechanisms of the actions. APPROACH AND RESULTS: Wild-type mice were used to determine the effect of U0126 on a high-fat diet or high-fat diet plus T0901317-induced transient dyslipidemia and liver injury. ApoE deficient (apoE(-/-)) mice or mice with advanced lesions were used to determine the effect of the combination of T0901317 and U0126 on atherosclerosis and hypertriglyceridemia. We found that U0126 protected animals against T0901317-induced transient or long-term hepatic lipid accumulation, liver injury, and hypertriglyceridemia. Meanwhile, the combination of T0901317 and U0126 inhibited the development of atherosclerosis in a synergistic manner and reduced advanced lesions. Mechanistically, in addition to synergistic induction of macrophage ABCA1 expression, the combination of U0126 and T0901317 maintained arterial wall integrity, inhibited macrophage accumulation in aortas and formation of macrophages/foam cells, and activated reverse cholesterol transport. The inhibition of T0901317-induced lipid accumulation by the combined U0126 might be attributed to inactivation of lipogenesis and activation of lipolysis/fatty acid oxidation pathways. CONCLUSIONS: Our study suggests that the combination of mitogen-activated protein kinase kinase 1/2 inhibitor and LXR ligand can function as a novel therapy to synergistically reduce atherosclerosis while eliminating LXR-induced deleterious effects.
Assuntos
Doenças da Aorta/prevenção & controle; Apolipoproteínas E/deficiência; Aterosclerose/prevenção & controle; Butadienos/farmacologia; Hidrocarbonetos Fluorados/farmacologia; Proteína Quinase 1 Ativada por Mitógeno/antagonistas & inibidores; Proteína Quinase 3 Ativada por Mitógeno/antagonistas & inibidores; Nitrilas/farmacologia; Receptores Nucleares Órfãos/agonistas; Inibidores de Proteínas Quinases/farmacologia; Sulfonamidas/farmacologia; Animais; Aorta/efeitos dos fármacos; Aorta/enzimologia; Aorta/patologia; Doenças da Aorta/enzimologia; Doenças da Aorta/genética; Doenças da Aorta/patologia; Apolipoproteínas E/genética; Aterosclerose/enzimologia; Aterosclerose/genética; Aterosclerose/patologia; Doença Hepática Induzida por Substâncias e Drogas/enzimologia; Doença Hepática Induzida por Substâncias e Drogas/patologia; Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle; Colesterol/metabolismo; Modelos Animais de Doenças; Sinergismo Farmacológico; Quimioterapia Combinada; Fígado Gorduroso/induzido quimicamente; Fígado Gorduroso/enzimologia; Fígado Gorduroso/patologia; Fígado Gorduroso/prevenção & controle; Feminino; Células Espumosas/efeitos dos fármacos; Células Espumosas/enzimologia; Células Espumosas/patologia; Células Hep G2; Humanos; Hidrocarbonetos Fluorados/toxicidade; Hipertrigliceridemia/induzido quimicamente; Hipertrigliceridemia/enzimologia; Hipertrigliceridemia/patologia; Hipertrigliceridemia/prevenção & controle; Fígado/efeitos dos fármacos; Fígado/metabolismo; Receptores X do Fígado; Masculino; Camundongos Endogâmicos C57BL; Camundongos Knockout; Proteína Quinase 1 Ativada por Mitógeno/metabolismo; Proteína Quinase 3 Ativada por Mitógeno/metabolismo; Receptores Nucleares Órfãos/metabolismo; Transdução de Sinais/efeitos dos fármacos; Sulfonamidas/toxicidade
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças da Aorta / Apolipoproteínas E / Sulfonamidas / Butadienos / Proteína Quinase 1 Ativada por Mitógeno / Proteína Quinase 3 Ativada por Mitógeno / Inibidores de Proteínas Quinases / Aterosclerose / Receptores Nucleares Órfãos / Hidrocarbonetos Fluorados Idioma: En Revista: Arterioscler Thromb Vasc Biol Assunto da revista: ANGIOLOGIA Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças da Aorta / Apolipoproteínas E / Sulfonamidas / Butadienos / Proteína Quinase 1 Ativada por Mitógeno / Proteína Quinase 3 Ativada por Mitógeno / Inibidores de Proteínas Quinases / Aterosclerose / Receptores Nucleares Órfãos / Hidrocarbonetos Fluorados Idioma: En Revista: Arterioscler Thromb Vasc Biol Assunto da revista: ANGIOLOGIA Ano de publicação: 2015 Tipo de documento: Article